AriBio Secures Japanese Patent for Alzheimer's Drug
The patent covers AR1001, an oral Alzheimer's treatment candidate using PDE-5 inhibition, as the company prepares Phase 3 results.
Updated on Nov. 3, 2026 in Alzheimer’s
AriBio has registered a Japanese patent for AR1001 (mirodenafil), an oral treatment candidate for Alzheimer's disease, and the European Patent Office has issued a notification of intended patent registration for the same drug. The patent covers the use of PDE-5 inhibitors for Alzheimer's and the inhibition of amyloid beta aggregation.
Why it matters
The patent filings extend intellectual property protection for an Alzheimer's candidate whose global Phase 3 trial, POLARIS AD, has been completed. Securing rights across Japan, Europe and the United States positions AR1001 for commercialization if its trial results support approval.
The figures come from formal patent registration and notification records, with patent rights projected to remain valid until 2040 if maintenance requirements are met. The efficacy of AR1001 in the POLARIS AD Phase 3 trial remains unresolved until topline results are presented at CTAD 2026.
The players
AriBio
AriBio is a South Korean biopharmaceutical company developing AR1001 as an oral treatment candidate for Alzheimer's disease.
SK Chemicals
SK Chemicals is a South Korean chemical and life sciences company that jointly filed the AR1001 patent with AriBio.
European Patent Office
The European Patent Office is the executive body of the European Patent Organisation that grants patents valid across its member states.
The details
AR1001 works by inhibiting PDE-5, an enzyme that degrades cGMP, a signaling molecule that dilates blood vessels, and is designed to target several pathological processes of Alzheimer's disease. AriBio and SK Chemicals jointly filed the patent, which also covers inhibiting the aggregation of amyloid beta into oligomers and fibrils.
Timeline
2025: AriBio acquired the U.S. patent for AR1001.
November 3, 2026: AriBio announced the Japanese patent registration and European Patent Office notification.
November 16, 2026: Topline Phase 3 results for AR1001 will be presented at CTAD 2026 in Boston.
Roadmap
The AR1001 patent filings follow AriBio's completed global POLARIS AD Phase 3 trial in early-stage Alzheimer's patients, and they precede the presentation of topline results at CTAD 2026. The filings extend the company's protection for an oral PDE-5 inhibitor approach to Alzheimer's as it moves toward a potential regulatory submission.
If AR1001 is approved, it would be an oral medication, a format that could be easier for patients to take than infusion-based therapies. Patients and caregivers should watch for the POLARIS AD Phase 3 results before expecting any change in available treatment options.
The takeaway
A patent covers the rights to a drug, not proof that it works, so the POLARIS AD Phase 3 results will be the real test for AR1001. Readers following Alzheimer's treatments should weigh the trial data once it is released.
What happens next
Topline Phase 3 results for AR1001 from the POLARIS AD trial will be presented at CTAD 2026 in Boston on November 16, 2026.
Further reading
Explore more on Alzheimer's research and treatment developments.
Source note: This article includes information reported by 조선일보.
